The results of this study should be further validated on a larger cohort of MS, AQP4-NMOSD and MOGAD patients so that we can adjust for further potential clinical confounders and analyses can be conducted to assess if the MOGAD and AQP4-NMOSD patients cause fatigue by different mechanisms without reducing the statistical power, although we suspect it is unlikely as there is no effect of MS versus the antibody-mediated group as a whole. The gene discussed is AQP4; the disease is myeloid sarcoma.